<DOC>
	<DOCNO>NCT01414868</DOCNO>
	<brief_summary>Background : Therapeutic outcome leukotriene receptor antagonist ( LTRA ) vary asthmatics，and 's ideal simple way prediction present . Objective：To investigate whether leukotriene D4 bronchial provocation test ( LTD4-BPT ) could indicator actual therapeutic outcome LTRA . Methods：A single centre , open-labeled trial perform 32 asthmatic positive LTD4-BPT result month . All subject categorize accord airway responsiveness leukotriene D4（PD20FEV1-LTD4） . Subjects receive montelukast therapy ( 10mg , per night ) , reassessment perform ( 3~5 ) day withhold LTRA . The primary end-point difference monthly PEFR . Secondary endpoint include difference FENO , PD20FEV1-LTD4 , PD20FEV1-MCh , pre-test FEV1 , ACT score , AQLQ symptom score , week 4 PEFmax PEFmin compare week 1 , gradual decrease use salbutamol day without use salbutamol .</brief_summary>
	<brief_title>Leukotriene D4 Bronchial Provocation Test ( LTD4-BPT ) Indicator Use Leukotriene Receptor Antagonist ( LTRA )</brief_title>
	<detailed_description>Our primary goal determine whether LTD4-BPT could clear indicator assess efficacy LTRA . Logistic regression model adopt statistical analysis . In model , pre-treatment PD20FEV1-LTD4 represent anticipated efficacy . The median PD20FEV1-LTD4 use classification asthmatic , low figure represent well anticipated outcome . Various variable , include difference pre- post- treatment FENO , PEFmax , PEFmin , PEFR , PD20FEV1 asthma score , introduce model represent actual efficacy LTRA . We aim test whether would certain parameter assist prediction anticipate outcome .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Leukotriene Antagonists</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>subject age 18 65，without acute upper respiratory tract infection past 2 week normal chest radiographic result baseline spirometry force expiratory volume one second ( FEV1 ) less 60 % predict withheld leukotriene receptor antagonist ( LTRA ) 5 day oral glucocorticosteroid antihistamine 3 day oral xanthenes longacting bronchodilator 2 day inhale corticosteroid longacting bronchodilator day well shortacting bronchodilator 4 hour prior measurement subject fall less 15 % FEV1 repetitive force respiration fall le 20 % FEV1 inhalation ethanol diluent control past confirmed history respiratory disease bronchial asthma ( COPD , bronchiectasis , pulmonary thromboembolism , etc . ) severe systemic disease（myocardial infarction , malignant tumor , etc.） poor cooperation test limit understanding , immunocompromised , participate clinical trial past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Leukotriene</keyword>
	<keyword>leukotriene receptor antagonist</keyword>
	<keyword>bronchial provocation test</keyword>
	<keyword>therapeutic outcome</keyword>
</DOC>